JAVELIN PARP Medley, a phase 1b/2 study of avelumab plus talazoparib: Results from advanced breast cancer cohorts
conference contribution
posted on 2020-02-01, 00:00authored byTimothy A Yap, Panagiotis Konstantinopoulos, Melinda L Telli, Smita Saraykar, J Thaddeus Beck, Matthew D Galsky, Jame Abraham, David R Wise, Mustafa Khasraw, Gabor Rubovszky, Mikhail Dvorkin, Anil A Joy, Mateusz Opyrchal, Daria Stypinski, Colombe Chappey, Ross Stewart, Rossano Cesari, Anita Scheuber, Aditya Bardia
JAVELIN PARP Medley, a phase 1b/2 study of avelumab plus talazoparib: Results from advanced breast cancer cohorts